---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-356947"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2021-12-14T23:59:59+00:00"
generated_at: "2026-06-28T01:15:25.510477+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics reports positive FT516 and FT596 Phase 1 data; FT516 gets RMAT designation for DLBCL

## Summary
- FT516: 6 of 10 CAR T-naive patients in ongoing response at median 9.1 months; 3 of 8 prior CAR T patients achieve CR.
- FDA granted RMAT designation for FT516 in relapsed/refractory DLBCL; dose expansion at 900M cells/dose initiated.
- FT596: 5 of 6 patients achieve objective response (4 CR) with single dose at 900M cells in combination with rituximab.
- FT596: 10 of 11 patients treated with second cycle continue in ongoing response; 3 in CR ≥6 months. No ICANS or GvHD observed.

## SEC filing metadata
- accession: 0001193125-21-356947
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2021-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312521356947/0001193125-21-356947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312521356947/d267979d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-356947
- JSON: https://secwatch.observer/filing/0001193125-21-356947.json
- Plain text: https://secwatch.observer/filing/0001193125-21-356947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.